With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder.

Viela Bio Inc. (NASDAQ:VIE) will receive $30 million up front and is eligible for undisclosed milestones, plus additional payments it described as “based, in part, on sales revenue.” The cash adds to a balance sheet that had about $189 million at June 30, and was augmented by $172.6 million in gross proceeds from Viela’s IPO, including its underwriters’ exercise of their overallotment option...